阿斯利康（AstraZeneca）于周五宣布了一项重组计划，旨在支持研发管线投资，带来约15亿美元的效益，以确保这家制药商继续朝着2030年实现800亿美元年收入的目标迈进。
AstraZeneca (AZN.L) on Friday announced a restructuring programme aimed at supporting pipeline investments with benefits of about $1.5 billion to keep the drugmaker on track to achieve its target of generating $80 billion in annual revenue by 2030.
这家英瑞合资制药商未详细说明该计划是否会涉及裁员，但表示预计该计划将产生最高达20亿美元的一次性重组费用，并在2029年底前基本完成。
The Anglo-Swedish drugmaker did not detail whether the plan would involve job cuts, but said it expects the programme to result in one-time restructuring charges of up to $2 billion and be largely completed by the end of 2029.
随着首席执行官苏博科（Pascal Soriot）试图向投资者保证最近的临床试验受挫并未动摇公司的长期前景，阿斯利康一直在加大对癌症、肥胖症和罕见病等治疗领域的投资。
AstraZeneca has been stepping up investments across therapy areas including cancer, obesity and rare diseases as CEO Pascal Soriot seeks to reassure investors that recent trial setbacks have not undermined the company's long-term prospects.
这些举措是在公布第三季度业绩的同时宣布的，该季度业绩超出了分析师预期，并促使该公司维持了2026年的业绩展望。
The moves were announced alongside third-quarter results, which surpassed analyst expectations and prompted the company to maintain its outlook for 2026.
英国竞争对手葛兰素史克（GSK）也在7月制定了一项价值19亿英镑（合25.4亿美元）的节约成本计划，以筹集资金资助药物开发并应对即将到期的专利损失。
British rival GSK (GSK.L) in July also laid out a cost-savings plan worth £1.9 billion ($2.54 billion) to generate cash to fund drug development and prepare for looming patent losses.